Targeting a Cure in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

Overview

Journal Transl Lung Cancer Res

Date 2025 Jan 20

PMID 39830747

Authors

Marie-Frederique DAmours

Cheryl Ho

Affiliations

Soon will be listed here.

References

Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J . Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10):1830-1840. PMC: 10082285. DOI: 10.1200/JCO.22.02186. View

Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S . Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC. N Engl J Med. 2023; 389(21):1935-1948. DOI: 10.1056/NEJMoa2306434. View

Dagogo-Jack I, Rooney M, Lin J, Nagy R, Yeap B, Hubbeling H . Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity. Clin Cancer Res. 2019; 25(22):6662-6670. PMC: 6858956. DOI: 10.1158/1078-0432.CCR-19-1436. View

Kasi P, Lee J, Pasquina L, Decker B, Vanden Borre P, Pavlick D . Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types. Clin Cancer Res. 2023; 30(4):836-848. PMC: 10870120. DOI: 10.1158/1078-0432.CCR-23-2693. View

Blinman P, Hughes B, Crombie C, Christmas T, Hudson M, Veillard A . Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?. Eur J Cancer. 2015; 51(12):1529-37. DOI: 10.1016/j.ejca.2015.05.022. View

Shaw A, Solomon B, Besse B, Bauer T, Lin C, Soo R . Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2019; 37(16):1370-1379. PMC: 6544460. DOI: 10.1200/JCO.18.02236. View

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

Wu Y, Dziadziuszko R, Ahn J, Barlesi F, Nishio M, Lee D . Alectinib in Resected -Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024; 390(14):1265-1276. DOI: 10.1056/NEJMoa2310532. View

Awidi M, Mier-Hicks A, Perimbeti S, Attwood K, Chen H, Jain P . Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?. Clin Lung Cancer. 2024; 25(6):509-518. DOI: 10.1016/j.cllc.2024.05.003. View

10.

Kwon M, Ku B, Olsen S, Park S, Lefterova M, Odegaard J . Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. Cancer Med. 2022; 11(15):2944-2956. PMC: 9359877. DOI: 10.1002/cam4.4663. View

11.

Kelly K, Altorki N, Eberhardt W, OBrien M, Spigel D, Crino L . Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015; 33(34):4007-14. DOI: 10.1200/JCO.2015.61.8918. View

12.

Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H . Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(34):3912-3917. DOI: 10.1200/JCO.22.00428. View

13.

Wu Y, John T, Grohe C, Majem M, Goldman J, Kim S . Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol. 2021; 17(3):423-433. DOI: 10.1016/j.jtho.2021.10.014. View

14.

Lin J, Schoenfeld A, Zhu V, Yeap B, Chin E, Rooney M . Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. J Thorac Oncol. 2019; 15(2):258-265. PMC: 7058505. DOI: 10.1016/j.jtho.2019.10.014. View

15.

Horn L, Whisenant J, Wakelee H, Reckamp K, Qiao H, Leal T . Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol. 2019; 14(11):1901-1911. PMC: 6823161. DOI: 10.1016/j.jtho.2019.08.003. View

16.

Wu Y, Tsuboi M, He J, John T, Grohe C, Majem M . Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(18):1711-1723. DOI: 10.1056/NEJMoa2027071. View